Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Breast Cancer Prevention: Where Are We?
Nangia JR, Rimawi MF. Nangia JR, et al. JCO Oncol Pract. 2021 Dec;17(12):720-722. doi: 10.1200/OP.21.00605. Epub 2021 Oct 7. JCO Oncol Pract. 2021. PMID: 34618555 No abstract available.
Elacestrant and the Promise of Oral SERDs.
Sanchez KG, Nangia JR, Schiff R, Rimawi MF. Sanchez KG, et al. Among authors: nangia jr. J Clin Oncol. 2022 Oct 1;40(28):3227-3229. doi: 10.1200/JCO.22.00841. Epub 2022 Jun 23. J Clin Oncol. 2022. PMID: 35737918 No abstract available.
Hair disorders in patients with cancer.
Freites-Martinez A, Shapiro J, Goldfarb S, Nangia J, Jimenez JJ, Paus R, Lacouture ME. Freites-Martinez A, et al. Among authors: nangia j. J Am Acad Dermatol. 2019 May;80(5):1179-1196. doi: 10.1016/j.jaad.2018.03.055. Epub 2018 Apr 14. J Am Acad Dermatol. 2019. PMID: 29660422 Free PMC article. Review.
Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer.
Hoyos V, Vasileiou S, Kuvalekar M, Watanabe A, Tzannou I, Velazquez Y, French-Kim M, Leung W, Lulla S, Robertson C, Foreman C, Wang T, Bulsara S, Lapteva N, Grilley B, Ellis M, Osborne CK, Coscio A, Nangia J, Heslop HE, Rooney CM, Vera JF, Lulla P, Rimawi M, Leen AM. Hoyos V, et al. Among authors: nangia j. Ther Adv Med Oncol. 2022 Jul 15;14:17588359221107113. doi: 10.1177/17588359221107113. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35860837 Free PMC article.
A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer.
Veeraraghavan J, Gutierrez C, De Angelis C, Davis R, Wang T, Pascual T, Selenica P, Sanchez K, Nitta H, Kapadia M, Pavlick AC, Galvan P, Rexer B, Forero-Torres A, Nanda R, Storniolo AM, Krop IE, Goetz MP, Nangia JR, Wolff AC, Weigelt B, Reis-Filho JS, Hilsenbeck SG, Prat A, Osborne CK, Schiff R, Rimawi MF. Veeraraghavan J, et al. Among authors: nangia jr. Clin Cancer Res. 2023 Aug 15;29(16):3101-3109. doi: 10.1158/1078-0432.CCR-22-3753. Clin Cancer Res. 2023. PMID: 37195235 Free PMC article.
The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer.
Ma CX, Luo J, Freedman RA, Pluard TJ, Nangia JR, Lu J, Valdez-Albini F, Cobleigh M, Jones JM, Lin NU, Winer EP, Marcom PK, Thomas S, Anderson J, Haas B, Bucheit L, Bryce R, Lalani AS, Carey LA, Goetz MP, Gao F, Kimmick G, Pegram MD, Ellis MJ, Bose R. Ma CX, et al. Among authors: nangia jr. Clin Cancer Res. 2022 Apr 1;28(7):1258-1267. doi: 10.1158/1078-0432.CCR-21-3418. Clin Cancer Res. 2022. PMID: 35046057 Clinical Trial.
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer.
Rimawi MF, Niravath P, Wang T, Rexer BN, Forero A, Wolff AC, Nanda R, Storniolo AM, Krop I, Goetz MP, Nangia JR, Jiralerspong S, Pavlick A, Veeraraghavan J, De Angelis C, Gutierrez C, Schiff R, Hilsenbeck SG, Osborne CK; Translational Breast Cancer Research Consortium. Rimawi MF, et al. Among authors: nangia jr. Clin Cancer Res. 2020 Feb 15;26(4):821-827. doi: 10.1158/1078-0432.CCR-19-0851. Epub 2019 Oct 29. Clin Cancer Res. 2020. PMID: 31662331 Clinical Trial.
Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer.
Anurag M, Jaehnig EJ, Krug K, Lei JT, Bergstrom EJ, Kim BJ, Vashist TD, Huynh AMT, Dou Y, Gou X, Huang C, Shi Z, Wen B, Korchina V, Gibbs RA, Muzny DM, Doddapaneni H, Dobrolecki LE, Rodriguez H, Robles AI, Hiltke T, Lewis MT, Nangia JR, Nemati Shafaee M, Li S, Hagemann IS, Hoog J, Lim B, Osborne CK, Mani DR, Gillette MA, Zhang B, Echeverria GV, Miles G, Rimawi MF, Carr SA, Ademuyiwa FO, Satpathy S, Ellis MJ. Anurag M, et al. Among authors: nangia jr. Cancer Discov. 2022 Nov 2;12(11):2586-2605. doi: 10.1158/2159-8290.CD-22-0200. Cancer Discov. 2022. PMID: 36001024 Free PMC article.
31 results